OPKO Health Analyst Price Targets

OPKO Health Inc

OPKNASDAQ

Trade with Public

$1.65

0.042.48%

마지막 업데이트: Oct 20, 9:28 AM

$1.65

0.042.48%

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

인수합병: OPKO Health (OPK) announced it will sell assets to Labcorp Holdings (LH) on Thursday, October 15, 2026 for $722M paid in cash

OPKO Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for OPKO Health (OPK).

Price Target Range — 9 Quarters

Analyst Consensus — 5 Analysts

3Buy

2Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$3Upside to Avg. PT+75.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 16, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$3→$4
Oct 16, 2026	Barrington Research	Michael Petusky	Upgrade	Market Perform→Outperform	—
Apr 29, 2026	Barrington Research	Michael Petusky	Downgrade	Outperform→Market Perform	—
Mar 2, 2026	Barrington Research	Michael Petusky	PT Cut	Outperform	$2→$2
Nov 20, 2025	JP Morgan	Brian Cheng	Initiate	Neutral	—
Oct 31, 2025	Jefferies	Maury Raycroft	Downgrade	Buy→Hold	$2→$2
Oct 30, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$2
May 1, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$2
Apr 25, 2025	JP Morgan	Eric Joseph	Initiate	Neutral	—
Apr 7, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$3
Mar 19, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$3
Mar 12, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$3
Mar 12, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$2
Mar 3, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$3
Feb 28, 2025	Barrington Research	Michael Petusky	Maintained	Outperform	$2
Jan 8, 2025	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$3
Nov 8, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$2
Sep 26, 2024	HC Wainwright & Co.	Yi Chen	Maintained	Buy	$3
Sep 20, 2024	Barrington Research	Michael Petusky	Maintained	Outperform	$2
Sep 17, 2024	Piper Sandler	Edward Tenthoff	Maintained	Overweight	$3

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

Piper Sandler analyst Edward Tenthoff reiterates OPKO Health (NASDAQ:OPK) with a Overweight and raises the price target from $3 to $4.

Benzinga Newsdesk

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Wall Street analysts changed outlook on top names. See all rating changes on analyst ratings page. PRPL, OPK, BF.B, MELI, RPD stocks downgraded.

Avi Kapoor

PRO
Barrington Research Downgrades OPKO Health to Market Perform

Barrington Research analyst Michael Petusky downgrades OPKO Health (NASDAQ:OPK) from Outperform to Market Perform.

Benzinga Newsdesk

PRO
Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

Barrington Research analyst Michael Petusky maintains OPKO Health (NASDAQ:OPK) with a Outperform and lowers the price target from $2.25 to $1.5.

Benzinga Newsdesk

PRO
JP Morgan Initiates Coverage On OPKO Health with Neutral Rating

JP Morgan analyst Brian Cheng initiates coverage on OPKO Health (NASDAQ:OPK) with a Neutral rating.

Benzinga Newsdesk

PRO
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

Jefferies analyst Maury Raycroft downgrades OPKO Health (NASDAQ:OPK) from Buy to Hold and lowers the price target from $2 to $1.6.

Benzinga Newsdesk

OPKO Health Inc

OPKO Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PRO
Barrington Research Downgrades OPKO Health to Market Perform

PRO
Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

PRO
JP Morgan Initiates Coverage On OPKO Health with Neutral Rating

PRO
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

뉴스

파트너 / 기고자

벤징가 글로벌

OPKO Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PRO
Barrington Research Downgrades OPKO Health to Market Perform

PRO
Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

PRO
JP Morgan Initiates Coverage On OPKO Health with Neutral Rating

PRO
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

People Also Watch

People Also Watch

OPKO Health Inc

OPKO Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PROBarrington Research Downgrades OPKO Health to Market Perform

PROBarrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

PROJP Morgan Initiates Coverage On OPKO Health with Neutral Rating

PROJefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

뉴스

파트너 / 기고자

벤징가 글로벌

OPKO Health Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

PROBarrington Research Downgrades OPKO Health to Market Perform

PROBarrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

PROJP Morgan Initiates Coverage On OPKO Health with Neutral Rating

PROJefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

People Also Watch

People Also Watch

PRO
Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

PRO
Barrington Research Downgrades OPKO Health to Market Perform

PRO
Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

PRO
JP Morgan Initiates Coverage On OPKO Health with Neutral Rating

PRO
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6

PRO
Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4

PRO
Barrington Research Downgrades OPKO Health to Market Perform

PRO
Barrington Research Maintains Outperform on OPKO Health, Lowers Price Target to $1.5

PRO
JP Morgan Initiates Coverage On OPKO Health with Neutral Rating

PRO
Jefferies Downgrades OPKO Health to Hold, Lowers Price Target to $1.6